Insiders MaxCyte, Inc.

Equities

Market Closed - London S.E. Other stock markets 11:35:06 2024-04-30 am EDT			5-day change	1st Jan Change
295 ^GBX	0.00%		-8.67%	-16.31%

Apr. 02	MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines	CI
Mar. 13	BTIG Adjusts Price Target on MaxCyte to $8 From $10, Maintains Buy Rating	MT

MaxCyte inks deal with Be Bio; Orcadian firms farmout	Apr. 02	AN
MaxCyte chief scientific officer leaves firm	Jan. 29	AN
MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer	Jan. 26	CI
MaxCyte's New President/CEO Takes Office	Jan. 02	MT
Technology Minerals identifies lithium at Knockeen	Dec. 12	AN
MaxCyte President/CEO to Step Down; Successor Appointed	Dec. 12	MT
MaxCyte Names New Chief Executive	Dec. 12	MT
MaxCyte, Inc Announces Executive Changes	Dec. 11	CI
MaxCyte, Inc Announces Executive Changes	Dec. 11	CI
Maxcyte Insider Sold Shares Worth $639,405, According to a Recent SEC Filing	Dec. 06	MT
Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing	23-09-06	CI
Insider Sell: Maxcyte	23-06-15	MT
MaxCyte Chair Richard Douglas buys USD350,000 in shares	23-03-30	AN
Insider Buy: Maxcyte	23-03-30	MT
MaxCyte appoints new chief financial officer, effective immediately	23-03-28	AN
Cell Engineering Company MaxCyte Appoints New CFO	23-03-28	MT
MaxCyte Names Douglas Swirsky CFO	23-03-27	MT
MaxCyte, Inc. Appoints Ron Holtz as EVP, Administration	23-03-27	CI
MaxCyte, Inc. Appoints Douglas J. Swirsky as Chief Financial Officer	23-03-27	CI
MaxCyte names members of new scientific advisory board	23-03-08	AN

No results for this search